A Case For Transparency: J&J Suit Targets Opaque PBM Affiliate’s Efforts To Exploit Copay Programs
Executive Summary
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.
You may also be interested in...
Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.
Specialty Drug ‘Doom Loop:’ Manufacturers Fight Against Becoming Primary Payers For Own Drugs
Drug Channels’ Adam Fein described the ongoing and escalating battle between manufacturers and payers over the cost of specialty drugs during a recent webinar.
Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.